SCHEDULE 13G/A: Janus Henderson Group Discloses 10.1% Stake in Mirum Pharmaceuticals

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a 10.1% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of April 30, 2025.

Summary

• Janus Henderson Group PLC, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 3 to Schedule 13G.
• The filing discloses their beneficial ownership in Mirum Pharmaceuticals, Inc. (CUSIP: 604749101).
• As of April 30, 2025, Janus Henderson Group PLC beneficially owns an aggregate of 4,998,777 shares of Mirum Pharmaceuticals' Common Stock.
• This ownership represents 10.1% of the class of securities.
• The reporting person holds shared voting power and shared dispositive power over all 4,998,777 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of an ownership stake. While it doesn't contain explicit positive or negative news from the company's operations, a significant stake by a reputable institutional investor can be perceived as a positive signal of confidence in the company's long-term prospects, hence a slightly positive score.

Positives

• The disclosure of a significant 10.1% stake by a major institutional investor like Janus Henderson Group PLC can be viewed as a vote of confidence in Mirum Pharmaceuticals, Inc.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant passive investment by an institutional asset manager in a pharmaceutical company. It reflects an investment decision by Janus Henderson Group PLC, rather than a strategic announcement from Mirum Pharmaceuticals itself. Such disclosures are common in the financial industry as part of regulatory compliance for large shareholders.

Stakeholder Impact

• Shareholders: The disclosure informs existing and potential shareholders about a significant institutional investor's stake, which can influence market perception and liquidity.
• Investment Professionals: Provides data for analysts tracking institutional ownership and market sentiment towards Mirum Pharmaceuticals.

Key Dates

Keywords

Mirum Pharmaceuticals, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Pharmaceuticals, Investment Adviser, Holding Company